Misbranded Drugs: A Danger To Physicians And Patients

by Pepper Hamilton LLP
Contact

Mail-order businesses, including pharmacies, bombard doctors by fax, phone, and Internet offering an assortment of name-brand medications and treatments at bargain prices. These new options tempt physicians with the promise of monetary savings for themselves and their patients, but they pose dangers. The Internet and unsolicited fax communications are the route to market for many “misbranded” – known more commonly as counterfeit – medications. “Misbranded” can mean a variety of things under federal law, including drugs that are imported from sources that have not registered with the Secretary of Health and Human Services.1 These unregistered – or unauthorized – companies often base their operations in foreign countries far beyond the protection of the U.S. Food and Drug Administration (FDA). When a physician purchases misbranded medications from unauthorized suppliers, he subjects himself to potential criminal fines and imprisonment – and, equally troubling, he may risk his patients’ safety.

The last 12 months have seen a surge in FDA investigations of foreign distributors and purchasers of counterfeit medications. On June 7, 2013, the FDA announced the seizure of 9,600 online pharmacies selling illegal, unapproved medications. As part of this sting, the FDA, along with international law enforcement, confiscated $41,104,386 worth of illegal product from foreign distributors2 and, worldwide, placed more than 200 individuals under arrest or under further investigation for a range of offenses.3

The FDA has also focused its attention on physicians who purchase from unauthorized distributors. One recent example involves Botox. From 2012 through 2013, Canadian distributors, not registered to sell medication in the United States, sold unapproved formulations of Botox to American physicians at bargain prices.4 The FDA notified more than 350 physicians that they had purchased Botox from an unregistered distributor and were in violation of the Federal Food Drug and Cosmetic Act (FDCA).5 According to the FDA, these medications posed risks to patient safety because they could lack necessary FDA warnings, contain ineffective or unknown ingredients, or could be improperly manufactured and shipped.6 Another recent example involves Avastin, an injectable medication used to treat cancer. Beginning in February 2012, the FDA investigated unlicensed Internet sellers of Avastin and found that Avastin purchased from these unauthorized distributors either contained the wrong active ingredient or contained no active ingredient at all, depriving cancer patients of critical treatment.7 In some cases, physicians were being sold Altuzan – an unapproved, Turkish form of the medication. The FDA sent a letter to medical practices that had purchased the counterfeit Avastin, warned them of the risk to patients and that the purchase of these medications may violate the FDCA.8

Medications or treatments brought into the United States from unregistered foreign distributors are considered misbranded under the FDCA. The consequences for purchasing misbranded pharmaceuticals can be serious. Violators may face criminal prosecution with a resulting maximum penalty of a one-year prison term, a $1,000 fine or both; penalties increase with repeated offenses.9 Ramifications extend beyond criminal prosecutions. Purchasing physicians face losing their medical licenses, professional reputations, and potential lawsuits by patients.

Physicians who choose not to purchase directly from manufacturers need to watch for the red flags misbranded medications often carry. Physicians should:

  • check the manufacturer’s Web site for alerts describing how to identify counterfeit versus authentic medications
  • when purchasing from an Internet provider, make sure the Web site is licensed by the Board of Pharmacy in the physician’s state
  • ask the manufacturer of the medication if the distributor is an “authorized distributor of record.” Only authorized distributors are permitted to legally distribute medications in the United States.
  • suspect that if the distributor does not provide invoices, literature, or brochures, or demands immediate payment, it is likely illegitimate, and
  • assess the product packaging. Medications shipped in shoddy, unprofessional boxes or unaccompanied by FDA labeling are likely misbranded.

By taking these steps, physicians can reduce the likelihood that they are purchasing illegal medications.

Endnotes

1 21 USC §§ 333(a), 352(o) (2012).

2 See Press Release, FDA, FDA takes action to protect consumers from dangerous medicines sold by illegal online pharmacies (June 27, 2013) (available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm358794.htm).

3 See Press Release, Interpol, International operation targets online sales of illicit medicines (June 27, 2013) (available at http://www.interpol.int/News-and-media/News-media-releases/2013/PR077).

4 See FDA Alert, Fraudulent Version of Botox Found in the United States (Apr. 26, 2013) (available at http://www.fda.gov/Drugs/DrugSafety/ucm349503.htm).

5 See Letter from FDA to Practitioners re: Purchasing Unapproved Medications from Foreign or Unlicensed Suppliers Could Result in Serious Harm to Patients (Nov. 30, 2012) (available at http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/ucm330610.htm).

6 Id.

7 See Press Release, FDA, FDA sends letters to 19 medical practices about counterfeit products and other unapproved cancer medicines (Feb. 14, 2012) (available at http://www.fda.gov/drugs/drugsafety/ucm291960.htm).

8 See, e.g., Letter from FDA to Paul D. Raymond (physician) re: Purchasing Medications from Foreign or Unlicensed Suppliers Could Result in Serious Harm to Patients (June 28, 2012) (available at http://www.fda.gov/downloads/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/UCM311165.pdf).

9 21 USC 333(a) (2012); U.S. v. Micheltree, 940 F.2d 1349 (10th Cir. 1991).

Written by:

Pepper Hamilton LLP
Contact
more
less

Pepper Hamilton LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.